1. Pink Sheet
  2. >>Product Reviews

FDA-Sponsor Interaction Could Increase Post-Pandemic With Virtual, In-Person Options

 
• By Derrick Gingery

Scott Gottlieb says that some meetings should remain in-person, but with virtual options proven effective, the FDA could offer more opportunities to talk to sponsors.

virtual meeting
Sponsors could find the FDA increasingly available post-pandemic thanks to the success of virtual meetings. • Source: Alamy

Former Commissioner Scott Gottlieb wants the US Food and Drug Administration to use the lessons from virtual meetings to expand its interaction with sponsors when in-person sessions return.

Gottlieb said in-person meetings during the application review cycle remain important and should be re-established when conditions warrant

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Product Reviews

More from Pink Sheet

Recent and Upcoming FDA Advisory Committee Meetings

 
• By Sue Sutter

Recent and upcoming US FDA advisory committee meetings and a summary of the topics covered.

UK Health Data Research Service Looks ‘Encouraging’ For Industry, But Implementation Details Will Be Key

 
• By Anabel Costa-Ferreira

Marcus Vass and Vladimir Murovec of international law firm Osborne Clarke tell the Pink Sheet what the government's planned HDRS might mean for industry, and how it compares with the European Health Data Space.

EU Health Data Space May Speed Up R&D Through Access To Multi-Omics & Clinical Record Data

 
• By Eliza Slawther

The European Health Data Space framework will allow companies to accelerate R&D processes and identify new molecular targets faster by facilitating centralized access to certain types of high-quality data, Finland’s Orion Pharma says.